Ftse Mib
36.685,83
1,29%
DAX
21.505,70
0,47%
S&P 500
6.035,13
0,68%
NASDAQ
19.616,25
1,16%
Bitcoin
98.470,68
-2,93%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Neurocrine Biosciences Inc (NBIX) Neurocrine Biosciences Inc (NBIX) Notizie

Neurocrine Biosciences Inc

NBIX
152,71
2,61 (1,74%)
Ultimo aggiornamento: 21:03:41
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
03/2/202522:19EDGAR2Form 144 - Report of proposed sale of securities
31/1/202522:34EDGAR2Form 144 - Report of proposed sale of securities
31/1/202522:33EDGAR2Form 144 - Report of proposed sale of securities
31/1/202522:32EDGAR2Form 144 - Report of proposed sale of securities
31/1/202522:32EDGAR2Form 144 - Report of proposed sale of securities
31/1/202522:31EDGAR2Form 144 - Report of proposed sale of securities
31/1/202522:29EDGAR2Form 144 - Report of proposed sale of securities
31/1/202522:29EDGAR2Form 144 - Report of proposed sale of securities
31/1/202522:28EDGAR2Form 144 - Report of proposed sale of securities
31/1/202522:28EDGAR2Form 144 - Report of proposed sale of securities
31/1/202522:28EDGAR2Form 144 - Report of proposed sale of securities
31/1/202522:27EDGAR2Form 144 - Report of proposed sale of securities
30/1/202522:01PRNUSNeurocrine Biosciences Announces Conference Call and Webcast..
30/1/202501:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/1/202514:30PRNUSNeurocrine Biosciences Announces Initiation of Phase 3..
27/1/202522:27EDGAR2Form 144 - Report of proposed sale of securities
27/1/202522:12EDGAR2Form 8-K - Current report
27/1/202522:05PRNUSNeurocrine Biosciences Announces Amendment to Strategic..
23/1/202522:05PRNUSAndrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior..
21/1/202522:05PRNUSNeurocrine Biosciences Announces Classic Congenital Adrenal..
17/1/202522:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/1/202522:19EDGAR2Form 144 - Report of proposed sale of securities
08/1/202514:30PRNUSNeurocrine Biosciences Announces Publication on Traditional..
06/1/202522:01PRNUSNeurocrine Biosciences to Present at the 43rd Annual J.P...
03/1/202522:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/12/202422:17EDGAR2Form 144 - Report of proposed sale of securities
20/12/202414:06EDGAR2Form 8-K - Current report
20/12/202414:00PRNUSNeurocrine Biosciences Announces Commercial Availability of..
19/12/202422:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202422:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/12/202422:29EDGAR2Form 144 - Report of proposed sale of securities
14/12/202400:55PRNUSNeurocrine Biosciences Announces FDA Approval of CRENESSITY™..
04/12/202400:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202419:41EDGAR2Form 144 - Report of proposed sale of securities
26/11/202422:01PRNUSNeurocrine Biosciences to Participate at Investor..
12/11/202423:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202401:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202414:30PRNUSNeurocrine Biosciences Presents New KINECT®-HD Data Showing..
05/11/202422:01PRNUSNeurocrine Biosciences to Participate at Investor..
04/11/202414:30PRNUSNeurocrine Biosciences Presents Breadth of Data..
04/11/202414:25PRNUSNeurocrine Biosciences Presents New Data on INGREZZA®..
02/11/202400:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/11/202413:31EDGAR2Form 8-K - Current report
30/10/202412:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
30/10/202412:02EDGAR2Form 8-K - Current report
30/10/202412:00PRNUSNeurocrine Biosciences Reports Third Quarter 2024 Financial..
11/10/202422:02EDGAR2Form 8-K - Current report
09/10/202422:01PRNUSNeurocrine Biosciences Announces Conference Call and Webcast..
30/9/202414:30PRNUSNeurocrine Biosciences Presents Interim Data Demonstrating..
19/9/202422:01PRNUSNeurocrine Biosciences to Participate at the TD Cowen 4th..
Apertura: 150,18 Min: 150,18 Max: 153,88
Chiusura: 150,10

La tua Cronologia

NASDAQ
NBIX
Neurocrine Biosciences
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci